Bright Minds Biosciences (NASDAQ: DRUG) has recently received a number of price target changes and ratings updates:
- 8/22/2026 – Bright Minds Biosciences was upgraded by Wall Street Zen from “sell” to “hold”.
- 8/20/2026 – Bright Minds Biosciences was downgraded by Oppenheimer Holdings, Inc. to “market perform”.
- 8/20/2026 – Bright Minds Biosciences had its “buy” rating reaffirmed by Benchmark Co..
- 8/19/2026 – Bright Minds Biosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $145.00 price target on the stock.
- 8/17/2026 – Bright Minds Biosciences had its “buy” rating reaffirmed by BTIG Research. They now have a $147.00 price target on the stock.
- 7/21/2026 – Bright Minds Biosciences was upgraded by Zacks Research from “hold” to “strong-buy”.
- 7/4/2026 – Bright Minds Biosciences was upgraded by Wall Street Zen from “strong sell” to “sell”.
Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.
The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.
Featured Articles
- Five stocks we like better than Bright Minds Biosciences
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Bright Minds Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.
